AAVantgarde Archives | Be Korea-savvy

Home / Posts tagged AAVantgarde

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease

AAVB-039 addresses the root cause of the disease, benefitting patients with any ABCA4 mutation AAVB-039 is currently being assessed in the CELESTE interventional clinical trial and we continue recruiting in our STELLA observational study MILAN, Oct. 02, 2025 (Korea Bizwire) – AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced [...]

AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025

MILAN, Sept. 05, 2025 (Korea Bizwire) – AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated clinical data from the LUCE-1 study at the 25th European Society of Retina Specialists (EURETINA) Annual Congress (EURetina 2025), taking place in Paris 4-7 September 2025. Data presented by Prof. [...]

AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025

MILAN, Aug. 28, 2025 (Korea Bizwire) – AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated LUCE-1 clinical data at the 25th European Society of Retina Specialists (EURETINA) Annual Congress (EURetina 2025), taking place in Paris 4-7 September 2025. AAVantgarde will also be presenting at the [...]

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

MILAN, Aug. 12, 2025 (Korea Bizwire) — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational [...]

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial

AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutation CELESTE is informed by the STELLA prospective natural history study, which is currently enrolling patients in the United States and Europe AAVB-039 uses AAVantgarde’s proprietary dual AAV intein platform. The platform has achieved [...]

AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting

MILAN, May 12, 2025 (Korea Bizwire) – AAVantgarde Bio (AAVantgarde), a clinical-stage international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the presentation of two abstracts at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), held May 4-8, 2025 in Salt Lake City (US). Prof. Simonelli, [...]

AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer

MILAN, April 28, 2025 (Korea Bizwire) – AAVantgarde Bio (AAVantgarde), a clinical-stage, international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the appointment of Mr. Rasmus Holm-Jorgesen as their Chief Financial Officer (CFO). Rasmus brings over 25 years of experience in strategy, finance and global operations within the biopharmaceutical [...]